Plerixafor(Sanofi)은 Recurrent Grade 1 Follicular Lymphoma 표적 치료제로, Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy 영역에서 개발·상용화 중입니다. 작용기전: targeting multiple pathological pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 32% (ClinicalTrials.gov NCT00822770). PK: t½ 0.3 h. 차별점: novel strategy to combat this challenging disease, potentially improving patient outcomes.
Recurrent Grade 1 Follicular Lymphoma
Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy
Active
gene therapy demonstrated sustained mitigation of pain events
lentiviral vector (LVV) transduction and CRISPR/Cas9-mediated gene correction
Humanized mouse models are essential for evaluating the engraftment capacity and genetic integrity of gene-mo
novel strategy to combat this challenging disease, potentially improving patient outcomes
targeting multiple pathological pathway
immune-mediated myocardial injury in myocarditis, and necrotizing vessel wall inflammation in vasculitis
apoptosis, limiting the efficacy of reperfusion therapies
biomarker and therapeutic target in metastatic CRC, and further elucidation of its regulatory network may fac
downregulation trend of E-cadherin expression
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.
Plerixafor(Sanofi)은 Recurrent Grade 1 Follicular Lymphoma 표적 치료제로, Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy 영역에서 개발·상용화 중입니다. 작용기전: targeting multiple pathological pathway. Phase 2에서 효능·안전성 신호를 검증 중입니다. 대표 임상 효능: ORR 32% (ClinicalTrials.gov NCT00822770). PK: t½ 0.3 h. 차별점: novel strategy to combat this challenging disease, potentially improving patient outcomes.
Recurrent Grade 1 Follicular Lymphoma
Multiple Myeloma; Post-transplant MRD-guided Maintenance Therapy
Active
gene therapy demonstrated sustained mitigation of pain events
lentiviral vector (LVV) transduction and CRISPR/Cas9-mediated gene correction
Humanized mouse models are essential for evaluating the engraftment capacity and genetic integrity of gene-mo
novel strategy to combat this challenging disease, potentially improving patient outcomes
targeting multiple pathological pathway
immune-mediated myocardial injury in myocarditis, and necrotizing vessel wall inflammation in vasculitis
apoptosis, limiting the efficacy of reperfusion therapies
biomarker and therapeutic target in metastatic CRC, and further elucidation of its regulatory network may fac
downregulation trend of E-cadherin expression
차트 로드 중…
임상시험이 많습니다. 임상시험 탭에서 Phase/Status 필터·검색을 사용하세요.
수집된 임상 필드(phase, status, endpoint 등) 기반 자동 요약입니다.